Market Place
Sourcing Support
Vir Biotechnology Announces Results for Tobevibart & Elebsiran
15 Nov 2024 //
BUSINESSWIRE
Vir Biotechnology Reports Q3 2024 Results and Update
31 Oct 2024 //
BUSINESSWIRE
Vir Biotechnology To Provide Q3 Results On October 31
17 Oct 2024 //
BUSINESSWIRE
Vir Biotech Announces Advances In Hepatitis Programs At AASLD Meeting
15 Oct 2024 //
BUSINESSWIRE
Vir Biotech to Participate in Wainwright 5th Hepatitis Conference
03 Oct 2024 //
BUSINESSWIRE
Vir Biotechnology Appoints O’Byrne As Chief Financial Officer
10 Sep 2024 //
BUSINESSWIRE
Vir Biotech Closes License Deal With Sanofi For T-Cell Engagers
09 Sep 2024 //
BUSINESSWIRE
Vir Biotechnology To Attend Morgan Stanley Healthcare Conference
22 Aug 2024 //
BUSINESSWIRE
Vir Licenses T-Cell Engagers From Sanofi
01 Aug 2024 //
BUSINESSWIRE
Vir Biotechnology Reports Q2 2024 Results And Strategic Restructuring
01 Aug 2024 //
BUSINESSWIRE
Vir Gains T-Cell Engagers From Sanofi, Cuts 25% Staff
01 Aug 2024 //
FIERCE BIOTECH
Vir Biotechnology To Report Q2 2024 Results On August 1
18 Jul 2024 //
BUSINESSWIRE
Vir Biotechnology Receives FDA IND Clearance for for Tobevibart and Elebsiran
26 Jun 2024 //
BUSINESSWIRE
Vir keeps pressure on Gilead with midphase hepatitis D data
05 Jun 2024 //
FIERCE BIOTECH
Tobevibart: Monotherapy/Combo Achieved Virologic Response In Hepatitis D
05 Jun 2024 //
BUSINESSWIRE
Vir Biotech At Goldman Sachs Healthcare Conference 2024
29 May 2024 //
BUSINESSWIRE
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
29 May 2024 //
BUSINESSWIRE
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
23 May 2024 //
BUSINESSWIRE
Vir`s Hepatitis Delta & B Data Accepted At EASL 2024
22 May 2024 //
BUSINESSWIRE
Vir`s SOLSTICE Data Featured At EASL 2024
21 May 2024 //
BUSINESSWIRE
Vir Provides Corporate Update, Q1 2024 Financial Results
02 May 2024 //
BUSINESSWIRE
Vir Biotechnology to Participate in BofA Healthcare Conference
30 Apr 2024 //
BUSINESSWIRE
How Vir found the one: CEO Marianne De Backer
19 Apr 2024 //
FIERCE BIOTECH
Vir Business Update, Q1 2024 Results On 5/2
11 Apr 2024 //
BUSINESSWIRE
Vir Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial
05 Mar 2024 //
BUSINESSWIRE
Vir Biotechnology Shares Rise 14% on Terminated Collaboration with GSK
23 Feb 2024 //
MARKETWATCH
GSK, Vir end flu drug alliance, removing key piece of $345M pact
23 Feb 2024 //
FIERCE BIOTECH
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
23 Feb 2024 //
BUSINESSWIRE
Vir Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
BUSINESSWIRE
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as CMO
20 Feb 2024 //
BUSINESSWIRE
Vir Biotechnology to Report Fourth Quarter 2023 Financial Results
01 Feb 2024 //
PRESS RELEASE
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses
13 Dec 2023 //
BUSINESSWIRE
Vir downsizes by 12%, will close St. Louis and Portland sites in 2024
13 Dec 2023 //
ENDPTS
Vir Biotechnology to Present Data from Ph 2 Chronic Hepatitis Delta and B Trials
13 Nov 2023 //
BUSINESSWIRE
Vir to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B
10 Nov 2023 //
BUSINESSWIRE
Vir Biotechnology Ranked the Fastest-Growing Company in North America
08 Nov 2023 //
BUSINESSWIRE
Vir Biotechnology Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Vir Biotechnology Appoints Jennifer Towne as Executive Vice President
30 Oct 2023 //
BUSINESSWIRE
Post-pandemic & flush with cash, Vir eyes frontiers in oncology and neurology
30 Oct 2023 //
ENDPTS
Vir Bio to Participate in the H.C. Wainwright 4th Annual HBV Conference
12 Oct 2023 //
GLOBENEWSWIRE
Vir Bio Announces Multiple Abstracts Highlighting New Chronic Hepatitis B
11 Oct 2023 //
GLOBENEWSWIRE
Vir Biotechnology to Report Third Quarter 2023 Financial Results
05 Oct 2023 //
GLOBENEWSWIRE
Vir Awarded BARDA Funding to Support Development of Antibody Platform
03 Oct 2023 //
GLOBENEWSWIRE
Vir Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388
20 Sep 2023 //
GLOBENEWSWIRE
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
29 Aug 2023 //
GLOBENEWSWIRE
New Vir CEO drops small molecules to `judiciously` use cash pile
04 Aug 2023 //
FIERCE BIOTECH
Vir Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Vir Biotechnology to Report Q2 2023 Financial Results on August 3, 2023
26 Jul 2023 //
GLOBENEWSWIRE
Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial
21 Jul 2023 //
REUTERS
Vir Biotechnology names Sasha Damouni Ellis as chief corporate affairs officer
07 Jul 2023 //
MMM ONLINE
Vir Biotechnology Appoints Sasha Damouni Ellis as EVP
29 Jun 2023 //
GLOBENEWSWIRE
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218
24 Jun 2023 //
GLOBENEWSWIRE
Vir Biotechnology Unveils Hidden Value
13 Jun 2023 //
SEEKING ALPHA
Vir Announces Abstracts Showing Hepatitis B and D Data Accepted for Presentation
07 Jun 2023 //
GLOBENEWSWIRE
Vir to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
05 Jun 2023 //
GLOBENEWSWIRE
Vir enlists J&J vet to run business development
19 May 2023 //
ENDPTS
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
17 May 2023 //
GLOBENEWSWIRE
Vir Biotechnology Appoints Jeff Calcagno, M.D., as EVP & Chief Business Officer
15 May 2023 //
GLOBENEWSWIRE
Vir Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial
11 May 2023 //
GLOBENEWSWIRE
Vir Biotechnology Provides Corporate Update and Reports 1Q 2023 FYR
04 May 2023 //
GLOBENEWSWIRE
